Exploring Psychedelics for Unmet Needs in Women's Reproductive Health.
Sara Shoar, Alissa Bazinet, Chaitra Jairaj
Psychedelic Medicine June 1, 2025 DOI: 10.1089/psymed.2024.0033 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Narrative mini-review Peer reviewed |
|---|---|
| Keywords | Postpartum depression Pregnancy Reproductive health Women’s health Psychedelics: compounds Women’s well-being |
| Citations | 2 |
| Key findings | There is a notable gap in research on the safety of psychedelic use during the female reproductive cycle, though potential therapeutic benefits for conditions like postpartum depression are suggested by interactions between psychedelics and female hormones. |
Abstract
In recent years, there has been a resurgence in research exploring the therapeutic potential of psychedelics for treating mental health disorders, coinciding with increasing psychedelic use and changing legal landscapes in the United States and globally. Despite these shifts, there remains a notable gap in understanding related to the safety of psychedelic use during critical stages of the female reproductive cycle, including menstruation, pregnancy, postpartum, breastfeeding, and menopause. This narrative mini-review provides a brief summary of recently published articles in this evolving therapeutic landscape and discusses critical public health implications for addressing psychedelic use for women's reproductive health. Studies have uncovered notable sex differences in users' subjective and physiological experiences of psychedelics. Interactions between psychedelics' mechanisms of action and female hormones suggest opportunities for addressing symptoms of menstruation, sexual dysfunction, chronic pelvic pain, menopause, and postpartum depression (PPD). Women in indigenous communities have traditionally used psychedelics as important components of healing rituals. Yet, potential risks associated with psychedelic use during the reproductive years, specifically during gestation and breastfeeding, underscore the importance of caution and informed decision-making. While there is therapeutic potential for psychedelics in women's reproductive health issues, comprehensive research pertaining to women is lacking. While rigorous scientific inquiry into the safety, efficacy, and mechanisms of action of psychedelics in women's health is paramount, public health messaging should dispel myths and promote risk reduction strategies. Collaboration with indigenous communities and vulnerable populations can enrich understanding and ensure culturally sensitive approaches. Through enhanced research and collaboration, psychedelics can be explored to potentially address unmet needs and enhance women's well-being across diverse reproductive contexts. Existing guidance fails to focus on recommendations for women, highlighting the need for harm reduction strategies.
Citations in the library
Cited by 3
- Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase) Psychiatry Research December 29, 2025
- Psychedelics and women’s mental health: the effects of female sex hormones on psychedelics’ efficacy and tolerability Molecular Psychiatry August 4, 2026
- New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants. Birth defects research May 1, 2026
Cites 32
- A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders JAMA Psychiatry March 1, 2017
- Gender differences in the subjective effects of MDMA Psychopharmacology March 5, 2001
- The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Neuropharmacology June 5, 2018
- Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways Current Topics in Behavioral Neurosciences 2017
- Psychedelics and connectedness Psychopharmacology August 9, 2017
and 27 more in the library